target directory

glp 1 receptor clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

Directory type

target

Association rule

normalized field

NCT06475586

Source recordAI-normalized

Effect of Semaglutide on the Inflammatory Response and Clinical Course of Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus

The clinical trial investigates the efficacy of semaglutide, a GLP-1 receptor agonist, in patients with Type 2 Diabetes Mellitus (DMT2) and moderate to severe plaque psoriasis. Given the increasing prevalence of both DMT2 and psoriasis, successful outcomes could position semaglutide as a dual-action therapy, enhancing its market potential. The competitive landscape includes other GLP-1 receptor agonists and psoriasis treatments, necessitating a thorough analysis of efficacy and safety profiles to ensure differentiation. The completion of this trial may also support expanded indications for semaglutide, potentially leading to increased market share and revenue streams for the sponsor, University of Banja Luka, and any future commercial partners.

AI analysis

Indication: Psoriasis Vulgaris

Modality: small molecule

Target: GLP-1 receptor

Sponsor: University of Banja Luka

Source URL: ClinicalTrials.gov

Source updated: Jul 01, 2024

Ingested: Jun 19, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: GLP-1 receptor

View original source fields

Condition raw: Psoriasis Vulgaris, Diabetes Type 2

Condition normalized: Psoriasis Vulgaris, Diabetes Type 2

Modality raw: small molecule

Modality normalized: small molecule

Target raw: GLP-1 receptor

Target normalized: GLP-1 receptor

Open report

NCT00849017

Source recordAI-normalized

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Two Dose Levels of Albiglutide Compared With Placebo in Subjects With Type 2 Diabetes Mellitus

Albiglutide, a GLP-1 receptor agonist developed by GlaxoSmithKline, aims to provide an effective treatment option for patients with Type 2 Diabetes Mellitus. The global diabetes market is projected to grow significantly, driven by increasing prevalence and demand for innovative therapies. Albiglutide's efficacy in reducing HbA1c levels positions it competitively against existing therapies, including other GLP-1 receptor agonists and insulin. The completion of this Phase 3 trial enhances GSK's portfolio and may facilitate market entry, pending regulatory approval. However, the competitive landscape remains robust, necessitating strategic positioning and potential partnerships to maximize market penetration.

AI analysis

Indication: Diabetes Mellitus, Type 2

Modality: protein therapy

Target: GLP-1 receptor

Sponsor: GlaxoSmithKline

Source URL: ClinicalTrials.gov

Source updated: Jan 09, 2017

Ingested: Jun 16, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: GLP-1 receptor

View original source fields

Condition raw: Diabetes Mellitus, Type 2

Condition normalized: Diabetes Mellitus, Type 2

Modality raw: protein therapy

Modality normalized: protein therapy

Target raw: GLP-1 receptor

Target normalized: GLP-1 receptor

Open report